Bridging the gap: The future of biosimilars regulations
Biosimilar vaccines and immunotherapeutic are innovative approaches in medical research. This commentary addresses the current disparities in regulations of biosimilar vaccines and immunotherapeutic products across different nations. It also navigates the benefits of global regulatory alignment and...
Saved in:
| Main Authors: | Anan S. Jarab, Shrouq R Abu Heshmeh, Ahmad Z. Al Meslamani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2362450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty
by: Lauren N. McGrath, et al.
Published: (2025-07-01) -
Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept)
by: Valentin Kopanarov, et al.
Published: (2025-07-01) -
Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01) -
BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01) -
RECOMBINANT HUMAN LUTEINIZING HORMONE FOR THE TREATMENT OF INFERTILITY: THE GENERATION OF PRODUCER CELL LINES
by: N. A. Orlova, et al.
Published: (2017-12-01)